Observational studyBMC geriatrics2026
DOME-HF 3 months: early outcomes of a diuretic day-hospital model for elderly patients with acute heart failure - a cardiogeriatric real-world experience.
Observational study in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Building an integrated cardiogeriatric heart failure pathway for very old adults: a four-year community case study from Hôpital La Porte Verte.Frontiers in health services · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) remains a leading cause of hospitalisation and mortality among older adults. Conventional inpatient management exposes frail elderly patients to significant iatrogenic risks. A diuretic day-hospital (DH) model may offer a safe, efficient, and patient-centred alternative. The DOME-HF programme integrates cardiology and geriatrics to deliver IV diuretics in an outpatient setting.
objectivesTo describe the clinical and geriatric profile, organisation of care, and short-term (3-month) outcomes of elderly patients managed for acute HF through a dedicated DH pathway.
methodsThis single-centre, retrospective observational study included all patients aged ≥ 65 years managed in the cardiogeriatric DH of Hôpital La Porte Verte (Versailles, France) between January and June 2025 for intravenous diuretic therapy. Sociodemographic, geriatric, and cardiologic characteristics, DH organisation, and 3-month outcomes were collected from medical records.
resultsForty patients (mean age 88 ± 6.8 years; 47.5% female) were analysed. Most lived at home (95%) with preserved autonomy (ADL 5.4 ± 0.7). The mean Charlson Comorbidity Index was 8.9 ± 2.3; 92.5% had chronic kidney disease, 67.5% atrial fibrillation, and 55% ischaemic heart disease. Median NT-proBNP at DH discharge (end of the DH episode) was 3141.5 pg/mL [IQR 1066.8–5244.5]. The median delay from referral to first DH session was 1 day [IQR 0–3], with 2.2 ± 1.6 sessions per patient. At 3 months, 8 patients (20%) were readmitted for HF and 16 (40%) for any cause; HF-related and all-cause mortality were 2.5% and 7.5%, respectively.
conclusionThe DOME-HF model appears feasible and safe for very elderly, multimorbid patients with acute HF. It provides rapid access to outpatient IV diuretic therapy with structured monitoring and short-term follow-up. To our knowledge, this is the first French cardiogeriatric diuretic DH programme reporting early outcomes. Larger comparative studies are needed to determine its impact on rehospitalisation, hospital burden, and functional outcomes in frail older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.